Introduction {#s1}
============

At most excitatory synapses in the central nervous system, such as the Schaffer collateral to CA1 synapses in the *stratum radiatum* of the hippocampus, excitatory neurotransmission is largely mediated by ionotropic AMPA-type (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA-type glutamate receptors. Yet, an emerging theme is that several conductances that limit membrane depolarization also make substantial contributions to the integrated excitatory post-synaptic potential (EPSP). For example, synaptically evoked Ca^2+^ influx into dendritic spines activates apamin-sensitive SK2-containing channels (small conductance Ca^2+^-activated K^+^ channels type 2; KCNN2), and their outward K^+^ conductance shunts the AMPAR-mediated depolarization, effectively reducing the EPSP ([@bib32]; [@bib16]). Kv4.2-containing channels are expressed in spines, close to, but not in the PSD ([@bib25]). Synaptic activity evokes Ca^2+^ influx through R-type voltage-gated Ca^2+^ channels in spines that boosts nearby Kv4.2-containing A-type K^+^ channels to further decrease the AMPA-mediated depolarization ([@bib43]). In addition, Ca^2+^-activated Cl^-^ channels are expressed in the spines and provide further inhibitory contributions ([@bib23]). Indeed, the sum of these repolarizing conductances may reduce the depolarizing AMPA-NMDA component by more than 50%. It is likely that each of these components can be regulated by a variety of second messenger pathways, greatly expanding the repertoire of targets to fine-tune synaptic transmission. For example, the Ca^2+^ sensitivity of SK2 channels is regulated in an activity-dependent manner by co-assembled protein kinase CK2 and protein phosphatase 2A ([@bib6]; [@bib1]) that are engaged by cholinergic signaling ([@bib18]). Moreover, the various contributions to synaptic responses may be dynamic, changing in response to distinct patterns of activity. Synaptic SK2-containing channels undergo protein kinase A (PKA)-dependent endocytosis upon the induction of LTP by theta burst pairing. The endocytosis of synaptic SK2-containing channels acts together with the PKA-dependent exocytosis of additional GluA1-containing AMPARs to mediate the expression of LTP ([@bib28]). Moreover, after the initial expression of LTP and loss of the SK2-containing channel contribution, homeostatic mechanisms act to re-establish the synaptic SK balance ([@bib29]). Similarly, Kv4.2-containing channels expressed in spines undergo PKA-dependent endocytosis after the induction of LTP ([@bib25]; [@bib20]). Therefore, the appropriate localization, spatial distribution, and orchestrated dynamics of these protein complexes provide a powerful regulator of excitatory neurotransmission and plasticity.

One class of proteins that plays a major role in synaptic organization and dynamics are the MAGUKs ([@bib14]), of which there are 10 subfamilies. These modular, usually multivalent scaffolds bind to synaptic receptors, channels, and signaling molecules to anchor them into their proper locations within the post-synaptic membrane ([@bib33]), creating a spatially and temporally restricted signaling domain ([@bib20]; [@bib11]; [@bib13]). Thus, within the post-synaptic density of excitatory synapses PSD-95 binds to NMDARs ([@bib12]), while SAP97 binds to AMPARs ([@bib22]; [@bib27]), and Shank and Homer may serve as modular organizers of the lattice of synaptic MAGUKs ([@bib37]; [@bib21]). However, the molecular mechanisms that engender synaptic localization and dynamics to SK2-containing channels are not well understood. There are two major isoforms of SK2 that are expressed in CA1 pyramidal neurons; SK2-L (long) has an extended intracellular N-terminal domain compared to SK2-S (short) and the two isoforms co-assemble into heteromeric channels ([@bib41]). In mice that selectively lack SK2-L expression, the SK2-S channels are expressed in the plasma membrane of dendrites and dendritic spines, yet fail to become incorporated into the post-synaptic membrane. Consequently, the SK2-containing channel contributions to EPSPs and plasticity are absent, and this loss of synaptic SK2-containing channel function enhances hippocampus-dependent learning tasks ([@bib2]). To identify proteins that might serve to localize synaptic SK2-containing channels, candidate SK2 interacting proteins were identified. One of them, the MAGUK protein MPP2 (membrane palmitoylated protein 2), is localized to the PSD and is essential for synaptic SK2-containing channel function.

Results {#s2}
=======

MPP2 interacts with SK2 {#s2-1}
-----------------------

Proteomic analyses (on high-resolution quantitative mass spectrometry) of SK2-containing channels immunoaffinity-purified from rodent whole brain membrane preparations suggested that the MAGUK protein, MPP2 might be an interaction partner. To further investigate this interaction, two newly generated antibodies targeting MPP2 were tested. Probing Western blots of proteins prepared from total mouse brain with either MPP2 antibody detected a predominant band at \~55 kDa. Similarly a single band, \~60 kDa, was detected in proteins prepared from HEK293 cells expressing FLAG-tagged MPP2, but not from mock transfected cells. For both brain and HEK293, pre-incubating the antibodies with the respective immunizing antigen abolished the bands ([Figure 1A,B](#fig1){ref-type="fig"}).10.7554/eLife.12637.003Figure 1.MPP2 interacts with SK2.(**A, B**) Western blots were prepared using mouse brain homogenate (Brain; 100 μg) or HEK293 cell extracts (1% of 10 -cm plate), either transfected to express FLAG-MPP2 (HEK) or empty plasmid (HEK mock). Duplicate lanes were prepared and one set was probed with the indicated MPP2 antibody (left panels) while the second set was probed with the same antibody after pre-absorbing with the immunizing antigen (right panels). Native MPP2 and transfected FLAG-MPP2 were detected only in the left panels. (**C**) Bar graphs illustrating abundance ratios determined for the indicated proteins in APs with two anti-MPP2 antibodies and IgG as a negative control. Horizontal lines denote threshold for specificity of co-purification. (**D**) Western blots of proteins prepared from HEK293 cells transfected with C8-tagged SAP97, Lin7A, Lin7C, and MPP2, and probed with anti-C8 antibody (left), anti-MPP2a antibody (middle), and anti-MPP2b antibody (right). The MPP2 antibodies recognized only MPP2.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.003](10.7554/eLife.12637.003)10.7554/eLife.12637.004Figure 1---figure supplement 1.Coverage of the primary sequences of all proteins shown in [Figure 1C](#fig1){ref-type="fig"}.Peptides identified by mass spectrometry are in red; those theoretically accessible but not detected in MS-analyses are in black, and peptides not accessible to MS-analyses under the settings used (peptides with mass values below 738 Da (\[absolute lower mass cutoff)\] or above 3000 Da (\[practical mass limit of the C18 RP-HPLC separation)\] are given in grey). The sum of amino acids in red is either related to the accessible primary sequence (relative coverage) or to the entire primary sequence (absolute coverage); transmembrane domains are underlined.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.004](10.7554/eLife.12637.004)10.7554/eLife.12637.005Figure 1---figure supplement 2.Coverage of the primary sequences of all proteins shown in [Figure 1C](#fig1){ref-type="fig"} (continued).See caption above.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.005](10.7554/eLife.12637.005)

Therefore, these two antibodies were used for affinity purifications combined with quantitative mass spectrometry (see Materials and methods). The results demonstrated that both antibodies robustly purified MPP2 and co-purified SK2 as well as SK3. In addition, these experiments identified DLG1 (SAP97) and Lin-homologs 7A and 7C as proteins co-assembling with MPP2 in rodent brain ([Figure 1C](#fig1){ref-type="fig"}; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). To rule out off-target effects of the two MPP2 antibodies, we tested their binding of C8-tagged of SAP97, Lin7A, or Lin7C, C8-tagged versions of each of these proteins after expression in HEK293 cells ([Figure 1D](#fig1){ref-type="fig"}). While all 8-tagged proteins were recognized by anti-C8 antibody only C8-MPP2 was recognized by anti-MPP2 antibodies ([Figure 1D](#fig1){ref-type="fig"}). MPP2, a member of the p55 Stardust family of MAGUK proteins, is predicted to be a 552 amino acid protein. Like most MAGUKs, MPP2 is a modular protein comprised of several distinct protein-protein interaction domains. There are two predicted L27 domains, followed by a single predicted PDZ domain, and then the SH3-HOOK-GK domains.

To test for direct interaction with SK2 channels, SK2-L and SK2-S, the SK2 isoforms that contribute to synaptic SK2-containing channels ([@bib2]), and either C8-MPP2 or PSD-95 were co-expressed in HEK293 cells. Immunoprecipitations were performed using an anti-SK2 antibody raised in guinea pig that is directed to the common C-terminal domain of the two SK2 isoforms, or using IgG as a control. Precipitated proteins were prepared as Western blots. Probing with anti-SK2 antibody that was raised in rabbits and directed against the same C-terminal sequence, demonstrated equivalent SK2 expression for input and after immunoprecipitation in each sample ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Probing with anti-C8 antibody detected a band of the appropriate apparent molecular weight for C8-MPP2 in the sample co-expressed with SK2-S plus SK2-L but not in the IgG control sample ([Figure 2A](#fig2){ref-type="fig"}). Probing with anti-PSD-95 antibody did not detect co-immunoprecipitation with SK2 ([Figure 2B](#fig2){ref-type="fig"}). The results demonstrated that C8-MPP2 but not PSD-95 was specifically co-precipitated with SK2. To examine the possibility that SAP97 interacts with SK2-S, C8-SAP97 was co-expressed in HEK293 cells together with either myc-SK2-S or GluA1, a known SAP97 interaction partner ([@bib27]). Immunoprecipitations were performed using anti-SK2 antibody, anti-GluA1 antibody, or IgG as a control. Western blotting with anti-C8 antibody revealed that C8-SAP97 only co-immunoprecipitated when co-expressed with GluA1, despite equivalent levels of input and immunoprecipitated proteins ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To test if MPP2 interacts with the unique N-terminal domain of SK2-L that is required for synaptic localization GST pull-down experiments were performed. While PDZ interactions are important for many MAGUK-partner protein interactions, the unique N-terminal domain of SK2-L does not contain a PDZ ligand motif and using the PDZ domain from MPP2 failed to show an interaction with the N-terminal domain of SK2-L. Therefore, the SH3-HOOK-GK domain of MPP2 was employed. This domain of MPP2 as well the SH3-HOOK-GK domains from SAP97, a MAGUK scaffold of a distinct subfamily from MPP2 ([@bib33]), or the SH3-HOOK-GK domain from CaCNB4, a non-canonical MAGUK protein that is a beta subunit for voltage-gated Ca^2+^ channels ([@bib42]) were prepared as GST-fusion proteins, bound to glutathione-agarose beads, and used as baits for the prey, the His-tagged N-terminal domain of SK2-L. A GST-fusion protein of the C-terminal domain of Kv1.4, and a His-fusion protein of PSD-93 (Chapsyn) were also prepared as positive interaction controls ([@bib31]). Coomassie staining and Western blotting with anti-GST antibody verified equivalent amounts of the baits, either as input or bound to beads ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). After exposure to the baits, bound prey proteins were eluted and prepared as Western blots. Probing with an anti-His antibody showed that the SH3-HOOK-GK domain from MPP2, but not from SAP97 or CaCNB4, specifically pulled down the N-terminal domain of SK2-L. As expected, the C-terminal domain of Kv1.4 pulled down PSD-93 ([Figure 2C](#fig2){ref-type="fig"}). Taken together these results suggest that MPP2 interacts with the unique N-terminal domain of SK2-L that is required for synaptic localization ([@bib2]).10.7554/eLife.12637.006Figure 2.MPP2 interacts with the N-terminal domain of SK2-L.(**A**) Co-immunoprecipitations. Western blots prepared from HEK cell lysates expressing SK2-S and SK2-L, either alone (mock) or together with C8-MPP2, immunoprecipitated with either anti-SK2 antibody or IgG (control), and probed for C8-MPP2. Adjacent blot shows input of C8-MPP2. (**B**) A similar experiment except using PSD-95 instead of C8-MPP2. PSD-95 is expressed but does not co-IP with SK2. (**C**) GST-pull-downs. Blot probed with anti-His antibody shows input prey proteins, His-SK2-L N-terminal domain and His-PSD-93. After exposure to GST-baits representing SH3-HOOK-GK domains of SAP97, CaCNB4, or MPP2, the His-SK2-L N-terminal domain was specifically retained by GST-MPP2. Positive control shows interaction between GST-C-terminal domain of Kv1.4 and His-PSD-93. Co-immunoprecipitations and GST-pull-downs were performed in triplicate.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.006](10.7554/eLife.12637.006)10.7554/eLife.12637.007Figure 2---figure supplement 1.Co-immunoprecipitations.(**A**) Immunoprecipitation and input of SK2-S plus SK2-L. Western blot probed with anti-SK2 antibody raised in rabbit. First three lanes show immunoprecipitates from transfected HEK293 cell lysates co-transfected with empty vector (mock), C8-MPP2, or PSD-95 (see [Figure 2](#fig2){ref-type="fig"}). Immunoprecipitations were performed using anti-SK2 antibody raised in guinea pig. Last three lanes show input material prior to immunoprecipitation. (**B**) Co-immunoprecipitation of C8-SAP-97 co-expressed in HEK293 cells with GluA1 but not with myc-SK2-S. Western blot using anti-C8 antibody detects input of C8-SAP-97 co-expressed with myc-SK2-S or GluA1. C8-SAP-97 co-immunoprecipitated with anti-GluA1 antibody but not with anti-SK2 antibody or IgG. (**C**) Western blot using anti-myc antibody detects myc-SK2-S co-expressed with C8-SAP-97, input and after immunprecipitation with anti-SK2 antibody. Higher MW bands correspond to aggregates of SK2-S. (**D**) Western blot using mouse monoclonal anti-GluA1 antibody detects GluA1 co-expressed with C8-SAP-97, for GluA1 input and GluA1 immunoprecipitated with rabbit polyclonal anti-GluA1 antibody.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.007](10.7554/eLife.12637.007)10.7554/eLife.12637.008Figure 2---figure supplement 2.GST-fusion protein expression.(**A**) Coomassie stained gel showing input bacterial lysates (left lanes) for the indicated GST-fusion proteins prior to being bound to glutathione agarose beads, and after binding to beads (right lanes). (**B**) Western blot of the gel in panel A, probed with anti-GST antibody.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.008](10.7554/eLife.12637.008)

MPP2 is a synaptic MAGUK protein {#s2-2}
--------------------------------

To examine the anatomical localization of MPP2, the anti-MPP2 antibodies were used for immunohistochemistry on hippocampal sections. At the light level, MPP2 was expressed throughout the hippocampus, and in area CA1, MPP2 was predominantly expressed in the dendritic arbors ([Figure 3A,B](#fig3){ref-type="fig"}). To determine the subcellular profile of MPP2 expression, pre- and post-embedding immuno-gold electron microscopy (iEM) was performed. Using pre-embedding techniques, sections from three animals revealed immunoparticles for MPP2 prominently labeled dendritic spines and dendritic shafts both along the plasma membrane and at intracellular sites. Post-synaptically, most immunoparticles for MPP2 were found in spines (84%; 436 particles) versus in dendrites (16%; 82 immunoparticles), with most immunoparticles in either compartment localized to the plasma membrane (84%; 365 immunoparticles in spines and 65%; 54 immunoparticles in dendrites). Next, post-embedding techniques were applied to determine if MPP2 is expressed in the post-synaptic density. Sections from three animals revealed that immunoparticles for MPP2 prominently labeled the post-synaptic densities of dendritic spines, as well as being detected in dendritic shafts ([Figure 3C,D](#fig3){ref-type="fig"}). Immunoparticles for MPP2 were not detected in *stratum pyramidale*, and were also absent pre-synaptically. Therefore, MPP2 is a synaptic MAGUK protein.10.7554/eLife.12637.009Figure 3.Localization of MPP2 in the hippocampus.(**A,B**) Light microscopic images of anti-MPP2 antibody labelling in hippocampus. MPP2 was present throughout the hippocampus and was prominent in the dendritic arbors of area CA1. (**C,D**) Electron micrographs of the hippocampus showing immunoparticles for MPP2 in the *stratum radiatum* of the CA1 region of the hippocampus, as detected using a post-embedding immunogold method. Immunoparticles for MPP2 were detected along the PSD (arrowheads) of dendritic spines (s) of CA1 pyramidal cells establishing asymmetrical synapses with axon terminal (at), as well as at extrasynaptic sites (arrows) of dendritic spines (s). Den, dendritic shaft. Scale bars in **C,D**: 0.2 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.009](10.7554/eLife.12637.009)

MPP2 is required for synaptic SK2-containing channel function {#s2-3}
-------------------------------------------------------------

To test whether MPP2 expression is important for synaptic SK2 channel function, two short hairpin RNAs (shRNAs) targeting the 3' untranslated region (3' UTR) of *Mpp2* mRNA were co-expressed in area CA1 by in utero electroporation (e14-16) of a plasmid that also directed expression of the fluorescent protein, GFP. Four- to five-week-old mice were then used to prepare fresh hippocampal slices. Whole-cell current clamp recordings were made from CA1 pyramidal neurons, either transfected, as reported by GFP expression, or non-transfected control cells. Synaptic stimulations of the Schaffer collateral axons evoked EPSPs. After establishing a stable baseline, apamin (100 nM) was applied to the slices. For control cells, apamin increased EPSPs to 144.4 ± 4.3% of baseline (n = 15; p\<0.0001), consistent with previous studies ([@bib32]; [@bib28]; [@bib19]). In contrast, apamin did not significantly affect EPSPs from transfected CA1 pyramidal neurons (94.6 ± 3.3%; n = 14) ([Figure 4A--C](#fig4){ref-type="fig"}).10.7554/eLife.12637.010Figure 4.MPP2 is required for synaptic SK2-containing channel function.(**A**) Time course of the normalized EPSP amplitude (mean ± s.e.m.) for baseline in control ACSF (Ctrl) and during wash-in of apamin (100 nM) as indicated above in MPP2 sh-transfected cells (open red symbols, n = 14) and non-fluorescent control cells (black symbols, n = 15) mice. (**B**) Average of 15 EPSPs taken from indicated shaded time points in aCSF (black) and 16--20 min after application of apamin (red); shaded areas are mean ± s.e.m for control non-fluorescent cells (ctrl, upper traces) and MPP2 sh-transfected cells (MPP2 sh, bottom traces). (**C**) Scatter plot of relative ESPS peak compared to baseline from the individual slices in panel A non-fluorescent control (ctrl, black symbols) and for MPP2 sh transfected (red symbols). Horizontal bar reflects mean response.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.010](10.7554/eLife.12637.010)

To further verify the efficacy of MPP2 knock-down, pre-embedding iEM was performed on hippocampal sections from MPP2 shRNA-transfected animals. To identify transfected CA1 pyramidal neurons, mouse anti-GFP antibody was detected using HRP-linked anti-mouse secondary antibody, and rabbit anti-MPP2 antibody was detected using immunogold particles coupled to anti-rabbit secondary antibody. Immunoparticles were then counted in the same number of profiles belonging both to dendritic spines and dendritic shafts on single sections. In spines on neurons expressing GFP, immunoparticles for MPP2 were reduced by 81% compared to spines on non-transfected control neurons (GFP-negative: 417 particles in 60 spines; GFP-positive: 101 particles in 60 spines; p\<0.001). A similar reduction (78%) was seen in dendritic shafts (GFP-negative: 155 particles in 25 dendrites; GFP-positive: 44 particles in 25 dendrites; p\<0.001) ([Figure 5A--D](#fig5){ref-type="fig"}).10.7554/eLife.12637.011Figure 5.Efficient knock-down of MPP2 expression in CA1 pyramidal neurons.Immunoreactivity for MPP2 in the CA1 region of the hippocampus, as revealed using a double-labelling pre-embedding method. (**A--D**) The peroxidase reaction end product (HRP) indicating GFP immunoreactivity filled CA1 pyramidal cells, whereas immunoparticles for MPP2 were mainly located along the plasma membrane and at intracellular sites of pyramidal cells. Immunoparticles for MPP2 were distributed in both GFP-positive (crossed arrows) and GFP-negative (arrows) dendritic spines (s) and dendritic shafts (Den) of pyramidal cells. However, there was a striking reduction of immunoparticles for MPP2 in GFP-positive profiles compared to GFP-negative profiles (see text). at, axon terminal. Scale bars in **A-D**: 0.2 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.011](10.7554/eLife.12637.011)

To demonstrate that the effects of shRNA transfection were specifically due to MPP2 knock-down, the shRNA (GFP) plasmid was co-transfected with a plasmid that directed expression of shRNA-immune MPP2 and a plasmid that expressed the red fluorophore, mApple. In doubly transfected neurons, apamin increased EPSPs similar to control, non-transfected neurons (148.2 ± 4.2%; n = 13; p\<0.0001, compared to shRNA knock-down) ([Figure 6A,B](#fig6){ref-type="fig"}). Thus, the consequences of the shRNA expression are mediated by knock-down of MPP2.10.7554/eLife.12637.012Figure 6.Co-expression of sh-immune MPP2 with MPP2 shRNA rescues synaptic SK2 function.(**A**) Time course of the normalized EPSP amplitude (mean ± s.e.m.) for baseline in control ACSF and during wash-in of apamin (100 nM) as indicated above in cells transfected MPP2 sh and MPP2 sh immune (n = 13). Inset: representative cell showing average of 15 EPSPs taken from indicated shaded time points in ACSF (black) and 16--20 min after application of apamin (red); shaded areas are mean ± s.e.m. (**B**). Scatter plot of relative ESPS peak compared to baseline from the individual slices for non-fluorescent control, MPP2 sh-transfected cells and MPP2 sh transfected with immune MPP2 (rescue). Horizontal bar reflects mean.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.012](10.7554/eLife.12637.012)

MPP2 selectively affects synaptic SK2-containing channels {#s2-4}
---------------------------------------------------------

There are at least two functionally distinct populations of apamin-sensitive SK2-containing channels in CA1 pyramidal neurons. One population resides in the spines and is activated by synaptically evoked NMDAR-dependent Ca^2+^ influx ([@bib32]). Another population resides in the dendrites and may be activated by somatic voltage steps that induce Ca^2+^ influx through voltage-gated Ca^2+^ channels ([@bib40]; [@bib17]; [@bib9]). To determine if MPP2 knock-down specifically affects synaptic SK2-containing channels or also affects SK2-containing channels in the dendrites transfected or control neurons were clamped at −55 mV and stepped to 20 mV; tail currents were elicited upon stepping back to −55 mV ([Figure 6A](#fig6){ref-type="fig"}). The apamin-sensitive component of the tail current ([Figure 7A](#fig7){ref-type="fig"} inset) effectively measures the SK2-containing channel component activated by somatic depolarization and showed that MPP2 knock-down did not significantly affect somatic activation of SK2-containing channels (ctrl: 41.9 ± 8.3 pA, n = 13; transfected: 53.7 ± 10.5, n = 7; P = 0.44) ([Figure 7A,B](#fig7){ref-type="fig"}). These results show that knocking down MPP2 expression disrupts the synaptic SK2-containing channel component but does not affect the channels in the dendrites that are activated by somatic voltage pulses.10.7554/eLife.12637.013Figure 7.Dendritic SK channel function is not reduced by MPP2 knock-down.(**A**) Representative traces of voltage-clamp recordings of IAHP after a 200 ms depolarizing pulse to 20 mV in an MPP2 sh-transfected cell. Apamin (red trace) blocks a component of the IAHP. Inset: subtraction of the traces before and after apamin application yielded the apamin-sensitive ImAHP. (**B**) Bar graph of apamin-sensitive tail current measured at 100 ms following repolarization to −55 mV. Data presented as mean ± s.e.m. for control non-fluorescent cells (n = 13) and MPP2 sh-transfected cells (n = 7).**DOI:** [http://dx.doi.org/10.7554/eLife.12637.013](10.7554/eLife.12637.013)

Loss of MPP2 reduces LTP {#s2-5}
------------------------

SK channel activity modulates the induction of synaptic plasticity ([@bib39]) and the activity-dependent endocytosis of synaptic SK2-containing channels contributes to the expression of LTP ([@bib28]). To determine the consequences of MPP2 knock-down and loss of synaptic SK2-containing channel activity on LTP, a theta burst pairing protocol was delivered in which Schaffer collateral stimulations were paired with back-propagating action potentials evoked by somatic current injections. In non-transfected CA1 pyramidal neurons, this induced LTP of 407.9 ± 46.3% (n = 8), while in transfected, MPP2 knock down neurons, LTP was significantly reduced (243.0 ± 14.8%; n = 13; p\<0.001) ([Figure 8](#fig8){ref-type="fig"}). Consistent with the loss of synaptic SK2-containing channels, MPP2 knock-down reduces LTP.10.7554/eLife.12637.014Figure 8.Loss of MPP2 reduces LTP.(**A**) Time course of the normalized EPSP amplitude (mean ± s.e.m.) from control non-fluorescent cells (ctrl, closed black symbols, n = 8) and MPP2 sh-transfected cells (MPP2, open red symbols, n = 13). The TBP protocol was delivered at time 0. Inset: representative cell showing average of 15 EPSPs taken from indicated shaded time points in ACSF (black) and 25--30 min after the induction of LTP (red); shaded areas are mean ± s.e.m. (**B**). Scatter plot of relative ESPS peak compared to baseline from the individual slices for non-fluorescent control (ctrl) and MPP2 sh-transfected cells. Horizontal bar reflects mean response.**DOI:** [http://dx.doi.org/10.7554/eLife.12637.014](10.7554/eLife.12637.014)

Discussion {#s3}
==========

The results presented here identify the synaptic MAGUK protein, MPP2 (p55), that is required for synaptic SK2-containing channel function. Synaptically evoked EPSPs in CA1 pyramidal neurons are increased by the SK channel blocker, apamin, but in CA1 pyramidal neurons expressing shRNAs directed against *Mpp2* mRNA apamin has no effect. MPP2 knockdown selectively affects synaptic SK2-containing channel function, as the SK2-containing channels expressed in the dendrites that are activated by somatic voltage steps are not altered. Consistent with the effects of MPP2 on synaptic SK2-containing channels, MPP2 knock-down reduces the expression of TBP-induced LTP by \~30%. This is slightly more than the component of LTP attributed to SK2 endocytosis in untransfected CA1 pyramidal neurons, \~17% ([@bib28]). This might reflect effects of MPP2 knock-down on other interaction partners (see below).

Previous results showed that synaptic SK2-containing channels are heteromeric assemblies that contain two isoforms of SK2, SK2-S and SK2-L. Compared to SK2-S, SK2-L has an additional 207 amino acids in the intracellular N-terminal domain and SK2-S is otherwise entirely contained in SK2-L ([@bib41]). In a transgenic mouse selectively lacking SK2-L, the SK2-S channels are expressed in the dendrites and even in the plasma membrane of dendritic spines, but they are specifically excluded from the PSD, and apamin fails to boost synaptically evoked EPSPs. Re-expressing SK2-L reinstates synaptic function as measured by apamin sensitivity of EPSPs ([@bib2]). These results implicated the unique N-terminal domain of SK2-L in directing SK2-containing channel synaptic localization and function, and suggested that the N-terminal domain of SK2-L might interact with a partner protein to engender PSD localization. Indeed, MPP2 binds to the unique N-terminal domain and knocking down MPP2 expression phenocopied the effect of SK2-L deletion on synaptic responses. MAGUK proteins recruit and stabilize AMPA and NMDA receptors in the PSD. Our results suggest that MPP2 similarly serves to stabilize SK2-containing channels in the PSD.

MPP2 is a member of the p55 Stardust subfamily of MAGUK scaffold proteins, named after the founding member MPP1, the major palmitoylated protein in erythrocytes ([@bib3]). Similar to other MAGUK scaffold proteins, MPP2 is modular, consisting of two L27 domains that may mediate homo- or heterophilic interactions, a single PDZ domain followed by SH3-HOOK-GK domains. Biochemical studies showed that MPP2 is enriched in the PSD fractions of rat brain, and pull-down assays to test for interactions suggested MPP2 may interact with itself as well as a number of other synaptic proteins, among them are PSD-95, SAP97, GKAP, CASK, GRIP, neuroligin, and CaMKII. The SH3-HOOK-GK domain of MPP2 was implicated in mediating these interactions ([@bib24]), similar to the interaction between MPP2 and the N-terminal domain of SK2-L.

The results presented here, using an unbiased approach also identified SK3 as immunopurifying with MPP2. SK2 and SK3 can form heteromeric channels in brain ([@bib41]), and SK3 is expressed in CA1 pyramidal neurons ([@bib5]). Different from SK2 that has two N-terminal isoforms, there is only one SK3 N-terminal isoform and it is similar to the extended N-terminal domain of SK2-L, harboring several islands of homology that might mediate interactions with MPP2.

The proteomics analyses of MPP2 also identified three additional scaffold proteins, the MAGUK protein, DLG1 (SAP97), as well as Lin7A and Lin7C as MPP2-interacting proteins. In epithelial cells, MPP7, a closely related member of the p55 Stardust family, dimerizes with Lin7 proteins, an interaction mediated by the C-terminal L27 domain, and the dimeric complex then associates with DLG1 via the N-terminal L27 domain that is insufficient to mediate DLG1 interactions in the absence of bound Lin7 ([@bib8]). DLG1 also binds the C-terminal PDZ ligand on the GluA1 subunit of AMPA receptors ([@bib27]). Indeed, upon the induction of LTP at Schaffer collateral to CA1 synapses, additional GluA1-containing AMPA receptors undergo exocytosis at a perisynaptic site followed by translocation into the post-synaptic membrane, increasing the AMPA component of EPSPs ([@bib44]). This exocytosis is dependent on the PDZ ligand at the C-terminus of the GluA1 subunit ([@bib29]; [@bib44]; [@bib38]), and exocytosis of GluA1-containing AMPA receptors is prerequisite to SK2-containing channel endocytosis; specifically blocking GluA1-containing AMPA receptor exocytosis prevents the rapid, subsequent endocytosis of SK2-containing channels ([@bib29]). Moreover, immunopurification of AMPA receptors from whole brain identified MPP2 as a protein that co-purified with AMPA receptors ([@bib36]). Synaptic SK2-containing channels reside in very close proximity to synaptic NMDA receptors within the PSD, providing a molecular microdomain that facilitates their functional coupling ([@bib32]; [@bib28]). PSD-95 interacts with NMDARs ([@bib26]), is crucial for the proper synaptic localization of ionotropic glutamate receptors ([@bib34]; [@bib15]), and interacts with SAP97 ([@bib10]). It will be interesting to determine whether MPP2 additionally interacts, directly or indirectly with PSD-95 to maintain the spatial synaptic relationship between SK2-containing channels and NMDA receptors. MPP2 contains multiple different protein-protein interaction domains that may bind not only receptors and channels but, additionally, signaling molecules as well as connections to the cytoskeleton. These observations raise the possibility that there is a dynamic protein lattice encompassing SK2-containing channels, AMPARs and NMDARs, and regulatory proteins that is woven together by molecular interactions between scaffold proteins to precisely tune synaptic responses during basal neurotransmission and plasticity.

Materials and methods {#s4}
=====================

Animal care {#s4-1}
-----------

All procedures involving animals were performed in accordance with the guidelines of Oregon Health and Science University (Portland, OR), animal care protocol number: IP00000191; University of Freiburg (Freiburg, Germany), Regierungspräsidium Freiburg, AZ: 35--9185/G-12/47; and University of Castilla-La Mancha (Albacete, Spain).

Molecular biology {#s4-2}
-----------------

MPP2 shRNAs were designed using an online algorithm (<http://sirna.wi.mit.edu>). Two sequences targeting the 3'UTR of mouse *Mpp2* mRNA (NM_016695; 1811--1833; 3620--3642) were synthesized for shRNA expression and cloned into a vector that drove their expression from the U6 promoter. This same plasmid also directed GFP expression from the ubiquitin promoter. For rescuing MPP2 knock-down, the MPP2 shRNA plasmids (GFP) were co-transfected with a plasmid expressing the MPP2 coding sequence, cloned between the CAG promoter and the 3' UTR from bovine growth hormone. This plasmid was co-transfected with a plasmid directing mApple expression from the ubiquitin promoter.

Antibodies {#s4-3}
----------

To generate antibodies to MPP2, rabbits were immunized with synthetic peptides representing amino acids 116--145 and 480--507 of mouse MPP2 (NP_057904). To test the antibodies using Western blots, mouse whole brains were homogenized in ice-cold homogenization buffer (0.32 M sucrose, 1 mM ethylenediaminetetraacetic acid, 1 mM ethyleneglycoltetraacetic acid, 10 mM Tris-HCl, pH 7.2, 0.4 mM phenylmethylsulfonyl fluoride). The resultant homogenate was subjected to centrifugation at 1000 *g* for 10 min to remove nuclei and debris. The protein concentration was determined with Lowry's method. Human embryonic kidney 293T (HEK293T) cells were transfected with pFLAG-CMV vector (Clontech, Palo Alto, CA) encoding mouse FLAG-MPP2 in a 10 cm dish. Cells were harvested in 0.5 ml of PBS. Homogenates and suspended cells were mixed with an equal volume of 2 x sodium dodecyl sulfate (SDS) sampling buffer (63 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 0.002% bromophenol blue), and denatured with 50 mM ( ± )-dithiothreitol at 55°C for 30 min. Proteins (100 µg of brain homogenates and 0.5 µl of cell lysates) were separated using 10% SDS-polyacrylamide gel electrophoresis, and electroblotted onto an Immobilon-P Transfer Membrane (Millipore, Billerica, MA). After blocking with 5% skimmed milk for 30 min, blotted membranes were incubated with primary antibodies (1 µg/ml) for 1 hr, then with peroxidase-conjugated secondary antibodies for 1 hr (Jackson ImmunoResearch, West Grove, PA; 1:10,000). Tris-buffered saline (10 mM Tris-HCl, pH 7.5, 150 mM NaCl) containing 0.1% Tween-20 was used as the dilution and washing buffer. Immunoreactions were visualized with the ECL chemiluminescence detection system, and captured using an ImageQuant LAS 500 (GE Healthcare, Buckinghamshire, UK). For specificity control, anti-MPP2a and anti-MPP2b (1 μg/ml) were mixed with 20 μg/ml of GST fusion proteins of the respective immunizing antigen.

Anti-SK2 antibodies have been previously characterized ([@bib28]; [@bib2]; [@bib4]). Mouse monoclonal anti-Myc (05--419), mouse monoclonal anti-GST (05--311), rabbit polyclonal anti-GluA1 (AB1504), and mouse monoclonal anti-GluA1 (MAB2263) antibodies were from EMD Millipore (Billerica, MA). Anti-6XHis mouse monoclonal antibody (37--2900) and anti-PSD-95 mouse monoclonal antibody (MA1-045) were from Thermo Scientific (Waltham, MA). Anti-GFP (ab92) mouse monoclonal antibody was from Abcam (Cambridge, MA). Mouse monoclonal C8 antibody was obtained as supernatant from Chessie 8 cells, LN 10300SP (National Cell Culture Center, Biovest, Minneapolis, MN). Secondary antibodies were from Santa Cruz Biotechnology (Dallas, TX), unless otherwise noted.

Proteomic analysis {#s4-4}
------------------

Proteomic analysis of MPP2 from rat brain was performed as described previously ([@bib36]; [@bib35]; [@bib7]). Briefly, affinity-purifications (APs) with anti-MPP2a, anti-MPP2b, and pre-immunization immunoglobulins (IgG) were performed on rat brain membrane fractions solubilized with CL-91 (Logopharm, March, Germany) and whole eluates were subjected to high-resolution mass spectrometry. Proteins retained in APs and identified by mass spectrometry were quantified by integration of peptide m/z signal intensities over time (peak volumes, PVs) that were extracted from FT full scans using MaxQuant (v.1.4.1.2; [<http://www.maxquant.org>]{.ul}; with integrated off-line mass calibration). Relative abundance of proteins in anti-MPP2 samples versus control (abundance ratio or rPV) was determined by the TopCorr method ([@bib7]) as the median of either (i) six individual peptide PV ratios of the best correlating protein-specific peptides (as determined by Pearson correlation of their abundance values; TopCorr6), or (ii) the 50% best of all individual peptide PV ratios (Top50). The linear dynamic range of the TopCorr method is about 4 orders of magnitude (detailed in \[[@bib7]\]). The data used for rPV determination (including peptide sequences, PV and rPV values, as well as the respective medians and selections methods) are summarized in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. The coverage of the primary sequences of all proteins shown in [Figure 1C](#fig1){ref-type="fig"} is presented in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.

Co-immunoprecipitation {#s4-5}
----------------------

HEK293 cells were transfected using Lipofectamine 2000 (Thermo Scientific). After 48 hr cells were washed, collected with PBS buffer, and pelleted. Cells were then solubilized with lysis buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM PMSF, and protease inhibitors (Hoffman La Roche, Basel, Switzerland) containing 1% β-D-dodecyl maltoside (Sigma-Aldrich, St. Louis, MO) for 30 min at RT. The lysate was centrifuged at 14,000 rpm for 20 min at 4°C. The supernatant was incubated with the indicated primary antibody for 30 min then 20 μl of protein A/G agarose beads (Thermo Scientific) were added for incubation overnight at 4°C with rotation. The beads were washed three times in washing buffer (mM) (20 HEPES, pH 7.5, 150 NaCl, 10 KCl, 2 EDTA, 10% glycerol). Proteins were eluted with 40 μl of 2X SDS sample buffer at 37°C. Bound and eluted proteins were subsequently separated by SDS-PAGE and transferred to PVDF membrane (BioRad, Hercules, CA). After blocking with 5% skimmed milk for 1 hr, the membrane was probed with the indicated antibodies over night at 4°C. HRP-conjugated secondary antibodies were applied for 30 min at RT. Blots were detected with SuperSignal ECL (Thermo Scientific) and developed with GeneMate Blue film (BioExpress, Kaysville, UT).

GST pull-downs {#s4-6}
--------------

The N-terminal domain of SK2-L (NP_001299834; 67--273) was cloned into pET33b for His tagged expression. Plasmids for expression of His-tagged rat PSD-93 (P85-T280) and GST-Kv1.4-ct (H570-V665) were gifts from Dr. Paul Slesinger ([@bib31]). For GST-fusion proteins, the SH3-HOOK-GK domains of mouse MPP2 (216--552; NM_016695.3), SAP97 (577--927; NM_007862.2), and CaCNB4 (45--371; NM146123.2) were cloned into pGex4T3. Expression levels of the GST-baits were determined by Coomassie staining and Western blotting with anti-GST antibody ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), or for His-prey, with anti-His antibody ([Figure 2](#fig2){ref-type="fig"}). GST pull-downs were performed as previously described ([@bib1]), with minor modifications. Glutathione agarose beads (Sigma-Aldrich) were resuspended and 50 μl of slurry was used per reaction. Beads were washed one time with pull-down wash buffer (PWB; 20 mM HEPES, pH 7.8, 10% glycerol, 100 mM KCl, 0.1 mM EDTA, 0.1 mM dithiothreitol \[DTT\], 0.1% Igepal CA-630 \[Sigma-Aldrich\]) and then incubated at 4°C for 2 hr with bacterial lysate containing the GST-fusion protein. Bead--protein complexes were washed one time with PWB followed by a 5 min wash at 4°C with PWB plus 0.1% BSA, and two 1 min washes with PWB. These \'baits\' were incubated at 4°C overnight with bacterial cell lysate from cultures expressing the His-tagged \'prey\', washed four times with PWB, added to SDS sample buffer, heated at 95°C for 5 min and resolved by SDS-PAGE. Following transfer the Western blot was probed with anti-His antibody.

Immunoelectron microscopy {#s4-7}
-------------------------

Immunohistochemical reactions at the electron microscopic level were carried out using immunogold methods as described previously ([@bib30]).

### Pre-embedding immunohistochemistry {#s4-7-1}

Single- and double-labelling methods were used. Briefly, in single-labelling experiments, free-floating sections were incubated in 10% NGS diluted in TBS. Sections were then incubated in anti-MPP2 antibodies (1--2 μg/ml diluted in TBS containing 1% NGS), followed by incubation in goat anti-rabbit IgG coupled to 1.4 nm gold (Nanoprobes, Yaphank, NY). Sections were postfixed in 1% glutaraldehyde and washed in double-distilled water, followed by silver enhancement of the gold particles with an HQ Silver kit (Nanoprobes). In co-labelling experiments, GFP immunoreactivity was visualized by the immunoperoxidase reaction, and MPP2 immunoreactivity was revealed with the silver-intensified immunogold reaction. Sections were then treated with osmium tetraoxide (1% in 0.1 M PB), block-stained with uranyl acetate, dehydrated in graded series of ethanol and flat-embedded on glass slides in Durcupan (Sigma-Aldrich) resin. Regions of interest were cut at 70--90 nm on an ultramicrotome (Reichert Ultracut E, Leica Biosystems, Barcelona, Spain) and collected on 200-mesh copper grids. Staining was performed on drops of 1% aqueous uranyl acetate followed by Reynolds's lead citrate.

### Post-embedding immunohistochemistry {#s4-7-2}

Briefly, ultrathin 80-nm-thick sections from Lowicryl-embedded blocks of the hippocampus were picked up on coated nickel grids and incubated on drops of a blocking solution consisting of 2% human serum albumin in 0.05 M TBS and 0.03% Triton X-100. The grids were incubated with MPP2 antibodies (10 μg/ml in 0.05 M TBS and 0.03% Triton X-100 with 2% human serum albumin) at 28°C overnight. The grids were incubated on drops of goat anti-rabbit IgG conjugated to 10 nm colloidal gold particles (Nanoprobes) in 2% human serum albumin and 0.5% polyethylene glycol in 0.05 M TBS and 0.03% Triton X-100. The grids were then washed in TBS and counterstained for electron microscopy with saturated aqueous uranyl acetate followed by lead citrate.

Ultrastructural analyses were performed in a Jeol-1010 electron microscope (Synaptic Structure Laboratory, School of Medicine, University of Castilla-La Mancha, Albacete, Spain). Electron photomicrographs were captured with an ORIUS SC600B CCD camera (Gatan, Munich, Germany). Digitized electron images were modified for color, brightness, and contrast with Adobe Photoshop, version 7.0. Labelled structures were classified based on unambiguous morphological information in each section. Axon terminals were identified by the presence of synapses and small round and/or large granular vesicles. Synapses were identified as parallel membranes separated by widened clefts that were associated with membrane specializations. Synapses displaying a prominent density on the post-synaptic side were characterized as asymmetrical. Dendritic spines were identified as small protrusions exhibiting membrane continuity with the dendritic shaft. Significance of immunogold particle labelling in GFP-positive versus GFP-negative spines and dendrites was assessed by ANOVA.

In utero electroporation {#s4-8}
------------------------

Timed-pregnant mice were anesthetized with isofluorane, their abdominal cavity cut open, and the uterine horns/sac exposed. Approximately 2 μl of DNA solution (\~2 mg/ml) was injected into the lateral ventricle of e14-e16 embryos, using a glass pipet pulled from thin walled capillary glass (TW150F-4, World Precision Instruments, Sarasota, FL) and a Picospritzer III microinjection system (Parker Hannifin, Hollix, NH). The head of each embryo within its uterine sac was positioned between tweezer-type electrodes (CUY650P10; Sonidel, Dublin, Ireland), and 5 square electric pulses (35 V; 50 ms; 1-s intervals) were passed using an electroporator (CUY21; Sonidel). After electroporation, the wall and skin of the abdominal cavity of the pregnant mouse was sutured-closed, and embryos were allowed to develop normally.

Slice preparation {#s4-9}
-----------------

Hippocampal slices were prepared from 4- to 5-week-old C57BL/6J mice. Animals were anesthetized with isoflurane and decapitated. The cerebral hemispheres were quickly removed and placed into cold artificial CSF (ACSF) equilibrated with carbogen (95% O~2~/5% CO~2~). Hippocampi and cortex were removed, placed onto an agar block, and transferred into a slicing chamber. Transverse hippocampal slices (300--350 μm) were cut with Leica VT1200s (Leica Biosystems, Buffalo Grove, IL) and transferred into a holding chamber containing regular ACSF. Slices were incubated at 34°C for 30 min and then at room temperature for ≥1 hr before recordings were performed. The slicing solution consisted of sucrose-ACSF (in mM): 70 sucrose, 80 NaCl, 2.5 KCl, 21.4 NaHCO~3~, 1.25 NaH~2~PO~4~, 0.5 CaCl~2~, 7 MgCl~2~, 1.3 ascorbic acid, 20 glucose and regular ACSF consisted of (in mM): 125 NaCl, 2.5 KCl, 21.5 NaHCO~3~, 1.25 NaH~2~PO~4~, 2.0 CaCl~2~, 1.0 MgCl~2~, 15 glucose, equilibrated with carbogen.

Electrophysiology {#s4-10}
-----------------

CA1 pyramidal cells were visualized with IR/DIC optics (Olympus BX51W1; Olympus Scientific Solutions, Waltham, MA) and a CCD camera. Whole-cell, patch-clamp recordings were obtained from CA1 pyramidal cells using a Multiclamp 700B (Molecular Devices, Sunnyvale, CA), digitized using an ITC-18 analog-to-digital converter, and transferred to a computer using Patchmaster software (Heka Instruments, Bellmore, NY). Patch pipettes (open pipette resistance, 2--4 MΩ) were filled with (in mM) 133 K-gluconate, 4 KCl, 4 NaCl, 1 MgCl~2~, 10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 4 MgATP, 0.3 Na~3~ guanosine triphosphate (Na~3~GTP), and 10 K~2~-phosphocreatine (pH 7.3). Electrophysiological records were filtered at 3.3 kHz and sampled at 10 kHz. Series resistance was electronically compensated to greater than 70%. A bias current was applied to maintain the membrane potential in current clamp at −65 mV. The input and residual series resistance in current clamp was determined from a 20 pA hyperpolarizing pulse applied at the end of each sweep. The input resistance in voltage clamp was determined from a 5 mV hyperpolarizing pulse applied at the beginning of each sweep. All recordings were from cells with a resting membrane potential less than −60 mV and a stable input resistance. All electrophysiological recordings were performed at 22--24°C, and data were not corrected for a junction potential of \~15 mV of the internal solution with respect to the bath ACSF.

Synaptic stimulation {#s4-11}
--------------------

EPSPs were recorded in whole-cell mode. Capillary glass pipettes (tip diameter, ∼5 μm) filled with ACSF and connected to Digitimer constant current stimulus isolation unit (AutoMate Scientific, Berkeley, CA) were used to stimulate pre-synaptic axons in *stratum radiatum* as described in Results. SR95531 (2--10 μM) and CGP55845 (1 μM) were present to reduce GABA~A~ and GABA~B~ contributions, respectively. To prevent epileptic discharges in the presence of GABAergic blockers, the CA3 region was microdissected out of slices used for EPSP recordings. LTP was induced by a theta burst pairing protocol, as previously described ([@bib28]).

Data analysis {#s4-12}
-------------

Data were analyzed using IGOR (WaveMetrics, Lake Oswego, OR). Data are expressed as mean ± SEM. Paired two-sample *t*-tests were used to determine significance of data in the same pathway, and non-parametric Wilcoxon Mann-Whitney two-sample rank test was used to determine significance between groups of data; p\<0.05 was considered significant.

Chemicals and solutions {#s4-13}
-----------------------

D-AP5, CNQX, CGP55845, and SR95531 were obtained from Tocris Bioscience (Ellisville, MO). All other chemicals were obtained from Sigma-Aldrich unless specified. All perfusing solutions were modified from regular ACSF unless otherwise noted.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Membrane palmitoylated protein 2 is a synaptic scaffold protein required for synaptic SK2-containing channel function\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Richard Aldrich as the Senior Editor.

The following individuals involved in review of your submission have agreed to reveal their identity: Leonard Kaczmarek and John Scott (peer reviewers).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is an interesting, generally well-written and straightforward article that defines a role for the synaptic scaffold protein membrane palmitoylated protein 2 (MPP2) in the modulation of synaptic SK2 channel action. The authors delineate the domains of interaction between MPP2 and the cytosolic domains of SK channels. Using an appropriate combination of proteomic, immunocytochemistry and electrophysiological techniques they show that manipulation of MPP2 affects SK2 channel modulation and synaptic long-term potentiation.

Essential revisions:

The data are not yet conclusive because there are five points that need to be more firmly established.

1\) The initial finding that led to the characterization of MPP2 as an interacting partner for SK2 was a mass spec-based analysis of SK2-containing channels immunopurified from rat brain. Other than the statement in the first sentence of the Results that this finding was the key to the all of the other experiments in the entire study, nothing is reported about this experiment.

A).The authors should provide data files of the peptide peak areas that were measured by mass spectrometry and used to calculate ratios shown in [Figure 1A](#fig1){ref-type="fig"}. How were those peptides chosen? How was the dynamic range established?

B\) The information in the Methods section is not adequate to establish the nature or specificity of the antibodies generated against MPP2. The authors need to state what antigen they used to generate the antibodies. They need to show a Western blot made with an entire lane of fractionated brain homogenate; the lane should show the molecular weights of all bands recognized by the antibody (including MPP2), and a second lane should show that the MPP2 band is not labeled when the antibody is preincubated with the antigen. The data in [Figure 1A](#fig1){ref-type="fig"} do not establish the specificity of the antibodies against MPP2. The authors have suggested that this data indicates that SAP-97, Lin7A and/or Lin7C co-assemble with MPP2 in rodent brain. However, the data are equally compatible with the conclusion that the two antibodies cross-react with SAP-97, Lin7A and/or Lin7C. Without this demonstration of specificity, the immunocytochemistry experiments carried out in [Figures 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"} are also not conclusive.

2\) The data in [Figure 1B and C](#fig1){ref-type="fig"} appear to establish that: 1. the channel protein SK2 can interact with MPP2 when the two proteins are expressed in HEK cells, and 2. SK2 does not interact with PSD-95 when the two proteins are co-expressed in HEK cells. However, the data would be more convincing if the authors indicated the molecular weight of the immunoprecipitated MPP2 band, and showed an entire lane, identifying any other cross-reacting bands. In the second paragraph of the subsection "MPP2 interacts with SK2 "the authors indicate a control as \"data not shown.\" These are important controls and the data should be presented.

3\) The data in [Figure 1D](#fig1){ref-type="fig"} presented problems for two reviewers:

A\) The data in [Figure 1D](#fig1){ref-type="fig"} shows that the SK2L isoform does not interact with Shank, SAP97, or CACNB4 when co-expressed; however, this data does not exclude interaction of SK2-S with SAP-97. In the subsection "MPP2 interacts with SK2", referring to [Figure 1D](#fig1){ref-type="fig"}, the authors state that \"...several other MAGUK proteins (Shank1, SAP97, CaCNB4) were prepared... and used as baits for the His-tagged N-terminal domain of SK2-L.\" Shank1 and CaCNB4 are not MAGUK proteins and do not have an SH3-HOOK-GK domain. The experiment in [Figure 1D](#fig1){ref-type="fig"} shows that the SH3-HOOK-GK domain of SAP-97 doesn\'t pull down SK2-L. The significance of its lack of interaction with Shank1 and CaCNB4 is less clear.

B\) A major part of the text that refers to [Figure 1](#fig1){ref-type="fig"} (subsection "MPP2 interacts with SK2", second paragraph) describes experiments showing that the SH3-HOOK-GK domain of MPP2 is the domain that is required for interaction with SK2-L. While [Figure 1D](#fig1){ref-type="fig"} may perhaps represent the data for this, there is no reference to [Figure 1D](#fig1){ref-type="fig"} in the text. In addition, the legend for [Figure 1D](#fig1){ref-type="fig"} makes no mention of SH3-HOOK-GK domains (but does refer to GST-pulldowns) and gives the impression that the full length proteins are being used here. The Methods do not give any information that allows one to identify what sequence is being used as bait in these experiments. Finally, the text erroneously refers to [Figure 1C](#fig1){ref-type="fig"} as showing that Kv1.4 pulls down PSD-93. In summary, either an important part of the text is missing or these experiments have to be described more clearly (or both).

4\) The immunohistochemistry and EM analysis that represent the core of MPP2 analysis are well done but need to be accompanied by intermediate resolution staining that shows the subcellular location of MPP2 in synapses of cultured neurons and whether or not the protein exhibits a distinct pattern of neuronal distribution from the marker protein PSD-95.

5\) The data in [Figure 4](#fig4){ref-type="fig"} is not a convincing demonstration of specific knockdown of MPP2. The authors should demonstrate the specificity of knockdown in cultured neurons where more quantitative measures are possible and where the possibility of off-target effects can be assessed. For example, is the expression of SAP97 altered?
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Author response

Essential revisions:

*The data are not yet conclusive because there are five points that need to be more firmly established.*

*1) The initial finding that led to the characterization of MPP2 as an interacting partner for SK2 was a mass spec-based analysis of SK2-containing channels immunopurified from rat brain. Other than the statement in the first sentence of the Results that this finding was the key to the all of the other experiments in the entire study, nothing is reported about this experiment.*

*A) The authors should provide data files of the peptide peak areas that were measured by mass spectrometry and used to calculate ratios shown in* [Figure 1A](#fig1){ref-type="fig"}*. How were those peptides chosen? How was the dynamic range established?*

Proteins retained in all anti-MPP2 APs and identified by mass spectrometry were quantified by integration of peptide m/z signal intensities over time (peak volumes, PVs). PVs were extracted from FT full scans using MaxQuant (v.1.4.1.2; <http://www.maxquant.org>; with integrated off-line mass calibration).

Relative protein abundance in a sample versus control (rPV, [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}) was determined by the TopCorr method (Bildl et al., MCP, 2012) as the median of either (i) six individual peptide PV ratios of the best correlating protein-specific peptides (as determined by Pearson correlation of their abundance values; TopCorr6) or (ii) the 50% best of all individual peptide PV ratios (Top50).

The linear dynamic range of the TopCorr method is about 4 orders of magnitude (detailed in Bildl et al., MCP, 2012).

The data used for rPV determination, including peptide sequences, PV and rPV values, as well as the respective medians and selections methods, were summarized and added to the revised manuscript as new [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. In addition, we have added as [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, the coverage of the primary sequences of all proteins shown in, now, [Figure 1C](#fig1){ref-type="fig"}.

These details have been added to the Methods section.

*B) The information in the Methods section is not adequate to establish the nature or specificity of the antibodies generated against MPP2. The authors need to state what antigen they used to generate the antibodies.*

Done, as requested.

*They need to show a Western blot made with an entire lane of fractionated brain homogenate; the lane should show the molecular weights of all bands recognized by the antibody (including MPP2), and a second lane should show that the MPP2 band is not labeled when the antibody is preincubated with the antigen.*

This is now part of revised [Figure 1](#fig1){ref-type="fig"}.

*The data in [Figure 1A](#fig1){ref-type="fig"} do not establish the specificity of the antibodies against MPP2. The authors have suggested that this data indicates that SAP-97, Lin7A and/or Lin7C co-assemble with MPP2 in rodent brain. However, the data are equally compatible with the conclusion that the two antibodies cross-react with SAP-97, Lin7A and/or Lin7C. Without this demonstration of specificity, the immunocytochemistry experiments carried out in [Figures 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"} are also not conclusive.*

The new Western blots (revised [Figure 1A, B](#fig1){ref-type="fig"}) show the antibodies have high specificity for MPP2. In addition we cloned and expressed, separately, C8-tagged SAP97, Lin7A and Lin7C in HEK293 cells and performed Western blots using the MPP2 antibodies; the expressed proteins were not detected. Probing with anti-C8 antibody confirmed the proteins were expressed (revised [Figure 1D](#fig1){ref-type="fig"}).

*2) The data in Figure 1B and C appear to establish that: 1. the channel protein SK2 can interact with MPP2 when the two proteins are expressed in HEK cells, and 2. SK2 does not interact with PSD-95 when the two proteins are co-expressed in HEK cells. However, the data would be more convincing if the authors indicated the molecular weight of the immunoprecipitated MPP2 band, and showed an entire lane, identifying any other cross-reacting bands.*

Done, as requested; new [Figure 2](#fig2){ref-type="fig"}.

*In the second paragraph of the subsection "MPP2 interacts with SK2 "the authors indicate a control as \"data not shown.\" These are important controls and the data should be presented.*

Done, as requested, please see new [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.

*3) The data in [Figure 1D](#fig1){ref-type="fig"} presented problems for two reviewers:*

*A) The data in [Figure 1D](#fig1){ref-type="fig"} shows that the SK2L isoform does not interact with Shank, SAP97, or CACNB4 when co-expressed; however, this data does not exclude interaction of SK2-S with SAP-97.*

To address this directly, we co-expressed C8-SAP97 with SK2-S and performed immunoprecipitation using anti-SK2 antibody. Probing a Western blot of the immunoprecipitated proteins for C8-SAP97 did not detect a band, although C8-SAP97 expression was verified by probing the input with C8 antibody. As a further control we co-expressed C8-SAP97 and GluA1, that are known to interact; immunoprecipitation using anti-GluA1 antibody, co-precipitated C8-SAP97. These data are shown in new [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.

*In the subsection "MPP2 interacts with SK2", referring to [Figure 1D](#fig1){ref-type="fig"}, the authors state that \"*...*several other MAGUK proteins (Shank1, SAP97, CaCNB4) were prepared*...

*and used as baits for the His-tagged N-terminal domain of SK2-L.\" Shank1 and CaCNB4 are not MAGUK proteins and do not have an SH3-HOOK-GK domain. The experiment in [Figure 1D](#fig1){ref-type="fig"} shows that the SH3-HOOK-GK domain of SAP-97 doesn\'t pull down SK2-L. The significance of its lack of interaction with Shank1 and CaCNB4 is less clear.*

CaCNB4 is a non-canonical MAGUK protein lacking N-terminal PDZ domains but having SH3-HOOK-GK domains (Chen et al., Nature, 2004; Van Petegam et al., Nature, 2004; [http://channelpedia.epfl.ch/ionchannels/9](http://channelpedia.epfl.ch/ionchannels/91)1). SHANK is not a MAGUK protein but is a synaptic scaffold with an SH3 domain. For clarity, we have eliminated SHANK1 from the revised manuscript and focus, in new [Figure 2C](#fig2){ref-type="fig"} on SAP97 and CaCNB4, two proteins with SH3-HOOK-GK domains that are in different subfamilies from MPP2.

*B) A major part of the text that refers to [Figure 1](#fig1){ref-type="fig"} (subsection "MPP2 interacts with SK2", second paragraph) describes experiments showing that the SH3-HOOK-GK domain of MPP2 is the domain that is required for interaction with SK2-L. While [Figure 1D](#fig1){ref-type="fig"} may perhaps represent the data for this, there is no reference to [Figure 1D](#fig1){ref-type="fig"} in the text. In addition, the legend for [Figure 1D](#fig1){ref-type="fig"} makes no mention of SH3-HOOK-GK domains (but does refer to GST-pulldowns) and gives the impression that the full length proteins are being used here. The Methods do not give any information that allows one to identify what sequence is being used as bait in these experiments. Finally, the text erroneously refers to [Figure 1C](#fig1){ref-type="fig"} as showing that Kv1.4 pulls down PSD-93. In summary, either an important part of the text is missing or these experiments have to be described more clearly (or both).*

This section has been thoroughly reworded and appropriate details are now included.

*4) The immunohistochemistry and EM analysis that represent the core of MPP2 analysis are well done but need to be accompanied by intermediate resolution staining that shows the subcellular location of MPP2 in synapses of cultured neurons and whether or not the protein exhibits a distinct pattern of neuronal distribution from the marker protein PSD-95.*

We are not sure why the reviewers ask for lower resolution staining in a preparation, neuronal cultures, that is further removed from the native condition, since we show clearly much higher resolution data to determine the subcellular localization of MPP2 in intact brain tissue, indeed at the level of individual synaptic membranes. If cultured neurons have synapses mirroring native synapses, we would see immunoreactivity for MPP2 -- or for PSD-95 -- in spines without resolution to the synapse itself that is only provided by post-embedding immunoEM. It is also unclear what additional information would be conveyed by comparisons to PSD-95. But in fact we have studied PSD-95 localization by iEM in previous work (Lin et al., Nat. Neurosci. 2008; Allen et al., Nat. Neurosci. 2011; Fukaya and Watanabe, J. Comp. Neurol. 2000), and we see no difference in the subcellular localization of MPP2 and PSD-95. Both proteins are integral PSD components and are also localized to a lesser extent to the dendrites. Consistent with other studies with PSD-95, MPP2 also appears to be distributed evenly across the PSD consistent with comprising part of a backbone that stabilizes its binding partners at the synapse (see DeGioris, Galbraith, Dosemeci, Chen and Reese, Brain, Cell Biol.2006)

5\) The data in [Figure 4](#fig4){ref-type="fig"} is not a convincing demonstration of specific knockdown of MPP2. The authors should demonstrate the specificity of knockdown in cultured neurons where more quantitative measures are possible and where the possibility of off-target effects can be assessed. For example, is the expression of SAP97 altered?

We respectfully disagree with the reviewers on this point. The data in original [Figure 4](#fig4){ref-type="fig"} (now, [Figure 5](#fig5){ref-type="fig"}) are quantified at very high resolution by comparing transfected and non-transfected spines and dendrites at the level of electron microscopy, and quite clearly demonstrate effective knockdown. We have analyzed particle distribution by ANOVA and added the appropriate p value (\< 0.001).

The reviewers request quantitation of knockdown in cultured neurons, but they present problems that are circumvented by the higher resolution quantitation of knockdown we have provided. In cultures, knockdown analysis would be measured by transfecting them with shRNA plasmids and subsequent Western blots. Since cultured neurons are difficult to transfect, quantifying efficiency of knockdown would be far less precise than the EM level quantification presented in original [Figure 4](#fig4){ref-type="fig"} (new [Figure 5](#fig5){ref-type="fig"}).

Also, while neuronal cultures have been well used to study some aspects of synaptic physiology, particularly AMPA and NMDA receptor mediated events and trafficking, they do not fully reflect native synapses. For example we have never recorded an apamin effect on EPSPs, nor even an SK current in cultured neurons. Thus, while cultured neurons may be useful for insights into glutamate receptors, it has become clear in the last several years that additional conductances make important contributions to post-synaptic responses in native spines and not all of these are recapitulated in neuronal cultures.

We very much appreciate the possibility of off-target effects and for this reason we applied the most direct and potent measure of knockdown specificity: re-establishment of the wild type phenotype by expression of an shRNA immune MPP2. It is indeed possible that SAP97 levels, or other synaptic proteins are reduced or altered by MPP2 shRNA expression. Using our online tool, we found no evidence that SAP97 mRNA would be knocked down by the MPP2 shRNAs. Thus if MPP2 knockdown is associated with altered levels of SAP97 this is more likely to be a consequence of MPP2 knockdown and compensatory changes at the level of the synapse than to a spurious cross-reaction of the shRNA with SAP97 mRNA. Our follow up studies are focused on collateral consequences of MPP2 loss for synaptic physiology. It is unclear how far the reviewers want us to go to search for possible off-target effects when we provide the explicit specificity control of the shRNA immune MPP2 rescuing the knockdown phenotype on which this work is focused.
